Fox Run Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Fox Run Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,677	Closed	-$317K	–	813
2022 Q1	$317K	Buy	+2,677	New	+$334K	0.18%	253
2021 Q3	–	Sell	-4,811	Closed	-$467K	–	673
2021 Q2	$467K	Buy	+4,811	New	+$390K	0.42%	60
2020 Q1	–	Sell	-6,069	Closed	-$330K	–	440
2019 Q4	$330K	Buy	+6,069	New	+$301K	0.27%	148
2019 Q3	–	Sell	-9,918	Closed	-$434K	–	648
2019 Q2	$434K	Buy	+9,918	New	+$559K	0.29%	113

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fox Run Management's BHVN Position: Q2 2022 in Review

Fox Run Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 2,677 shares — an estimated $317K sold.

Fox Run Management first reported a position in BHVN in Q2 2019 and held it in 4 quarters. The position peaked at $467K in Q2 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Fox Run Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Fox Run Management sold 2,677 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $317K.
Fox Run Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019 and held it in 4 quarters.
Fox Run Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $467K in Q2 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Fox Run Management's 13F filing for Q2 2022, filed 12 Aug 2022.